Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione
2. 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
3. Ntbc Cpd
4. Orfadin
1. 104206-65-7
2. Orfadin
3. 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione
4. Nitisone
5. Ntbc
6. 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
7. 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
8. 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione
9. Sc 0735
10. Sc-0735
11. 2-(alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
12. 1,3-cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]-
13. 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
14. Chembl1337
15. Chebi:50378
16. 1,3-cyclohexanedione, 2-(2-nitro-4-(trifluoromethyl)benzoyl)-
17. Mfcd01752192
18. Sc0735
19. K5bn214699
20. Nitisinone [inn]
21. Nitisinone [usan:inn]
22. Nitisinona
23. Nitisinonum
24. Smr002529592
25. Orfadin (tn)
26. Nitisinone (jan/usan/inn)
27. Unii-k5bn214699
28. Nityr
29. Fe-0200
30. 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
31. Nitisinone [mi]
32. Nitisinone [jan]
33. Nitisinone [usan]
34. Nitisinone [vandf]
35. Nitisinone [mart.]
36. Nitisinone [who-dd]
37. Bidd:pxr0129
38. Mls004774025
39. Mls006011955
40. Nitisinone [ema Epar]
41. Schembl338795
42. Ambz0071
43. Gtpl6834
44. Dtxsid9042673
45. Nitisinone [orange Book]
46. Nitisinone, >=95% (hplc)
47. Schembl15996621
48. Hms3740a15
49. Hms3870k03
50. Bcp15276
51. Hy-b0607
52. Bdbm50088804
53. Nsc773149
54. Rb3134
55. S5325
56. Akos015891363
57. Akos015994590
58. Zinc100014475
59. Am62666
60. Ccg-222085
61. Db00348
62. Ex-6233
63. Nsc-773149
64. Sb19017
65. Ncgc00185778-01
66. Ncgc00185778-02
67. Ncgc00185778-04
68. Ncgc00185778-07
69. Ac-26934
70. Sy047291
71. Db-014936
72. Ft-0672739
73. D05177
74. A800922
75. Sr-01000940576
76. J-505680
77. Q3877355
78. Sr-01000940576-2
79. Ntbc; Nitisone; Sc0735; Sc 0735; Sc-0735
80. Z1514110653
81. 1,3-cyclohexanedione,2-[2-nitro-4-(trifluoromethyl)benzoyl]-
82. 2-(2-nitro-4-(trifluoromethyl)-benzoyl)cyclohexane-1,3-dione
83. 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione;nitisinone
84. 2-(.alpha.,.alpha.,.alpha.-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
Molecular Weight | 329.23 g/mol |
---|---|
Molecular Formula | C14H10F3NO5 |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 2 |
Exact Mass | 329.05110691 g/mol |
Monoisotopic Mass | 329.05110691 g/mol |
Topological Polar Surface Area | 97 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 524 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Orfadin |
PubMed Health | Nitisinone (By mouth) |
Drug Classes | Gastrointestinal Agent |
Drug Label | Orfadin contains nitisinone, which is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1). Nitisinone occurs as white to... |
Active Ingredient | Nitisinone |
Dosage Form | Capsule |
Route | Oral |
Strength | 5mg; 2mg; 10mg |
Market Status | Prescription |
Company | Swedish Orphan |
2 of 2 | |
---|---|
Drug Name | Orfadin |
PubMed Health | Nitisinone (By mouth) |
Drug Classes | Gastrointestinal Agent |
Drug Label | Orfadin contains nitisinone, which is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1). Nitisinone occurs as white to... |
Active Ingredient | Nitisinone |
Dosage Form | Capsule |
Route | Oral |
Strength | 5mg; 2mg; 10mg |
Market Status | Prescription |
Company | Swedish Orphan |
Used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.
FDA Label
Hereditary tyrosinemia type 1 (HT 1)
Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.
Alkaptonuria (AKU)
Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).
Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.
Treatment of tyrosinemia type 1
Hereditary tyrosinemia type 1 occurs due to a deficiency in fumarylacetoacetase (FAH), the final enzyme in the tyrosine catabolic pathway. Nitisinone inhibits catabolism of tyrosine by preventing the catabolic intermediates. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of HT-1.
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
A16AX04
A16AX04
A16AX04
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX04 - Nitisinone
Absorption
The capsule and liquid formulations are bioequivalent in both the plasma concentration-time curve and maximum plasma concentration (Cmax).
~54 hours
Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolyase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with hereditary tyrosinemia type 1 (HT-1), nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2020-08-28
Pay. Date : 2020-08-06
DMF Number : 33948
Submission : 2019-07-17
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2017-02-01
Pay. Date : 2016-12-26
DMF Number : 31250
Submission : 2017-01-02
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30680
Submission : 2016-10-19
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-09-21
Pay. Date : 2021-08-02
DMF Number : 36026
Submission : 2021-07-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35810
Submission : 2021-03-31
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in th...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : Alven Laboratories is a pharmaceutical company specializing in the development, scale-up, and production of original and generic Active Pharmaceutical Ingredients (APIs). With expe...
About the Company : Anhui Biochem Pharmaceutical Co., Ltd. is a high tech enterprise which has integrated R&D, production and marketing specializing in synthetic technology of chiral compounds. We has...
About the Company : Danesh Kimia Pharmed Co. was established on 2011 by industrial and university researchers in order to invest on the production of new pharmaceutical molecules and their ready to us...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Established in the early 90’s SCL offers a wide range of Active Pharmaceutical Ingredients and Intermediates to its customers worldwide. SCL’s products are exported to Europe, ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Italy
Brand Name : NITISINONE DIPHARMA
Dosage Form : Hard Capsules
Dosage Strength : 2 mg
Packaging : 60 UNITS 2 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Turkey
Brand Name : Tisinon
Dosage Form : Capsule
Dosage Strength : 5MG
Packaging : 60 Capsules
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Regulatory Info :
Registration Country : Sweden
Brand Name : Orfadin
Dosage Form : KAPSEL, HÅRD
Dosage Strength : 20 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Orfadin
Dosage Form : KAPSEL, HÅRD
Dosage Strength : 10 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Orfadin
Dosage Form : KAPSEL, HÅRD
Dosage Strength : 5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Orfadin
Dosage Form : Nitisinone 2Mg 60 Units Oral Use
Dosage Strength : 60 cps 2 mg bottle
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Orfadin
Dosage Form : Capsule, hard
Dosage Strength : 10 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Orfadin
Dosage Form : Capsule, hard
Dosage Strength : 2 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : ORFADIN
Dosage Form : Hard Capsule For Oral Use
Dosage Strength : 2 mg
Packaging : 60 UNITS 2 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : ORFADIN
Dosage Form : Hard Capsule Oral Use Hdpe
Dosage Strength : 20 mg
Packaging : 60 UNITS 20 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MDK-NITISINONE
Dosage Form : CAPSULE
Dosage Strength : 10MG
Packaging : 60
Approval Date :
Application Number : 2457733
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MDK-NITISINONE
Dosage Form : CAPSULE
Dosage Strength : 2MG
Packaging : 60
Approval Date :
Application Number : 2457717
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MDK-NITISINONE
Dosage Form : CAPSULE
Dosage Strength : 5MG
Packaging : 60
Approval Date :
Application Number : 2457725
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORFADIN
Dosage Form : CAPSULE
Dosage Strength : 5MG
Packaging : 60
Approval Date :
Application Number : 2459701
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORFADIN
Dosage Form : CAPSULE
Dosage Strength : 10MG
Packaging : 60
Approval Date :
Application Number : 2459728
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORFADIN
Dosage Form : CAPSULE
Dosage Strength : 20MG
Packaging : 60
Approval Date :
Application Number : 2459736
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORFADIN
Dosage Form : CAPSULE
Dosage Strength : 2MG
Packaging : 60
Approval Date :
Application Number : 2459698
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ORFADIN
Dosage Form : SUSPENSION
Dosage Strength : 4MG/ML
Packaging : 90ML
Approval Date :
Application Number : 2469693
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : NITISINONE TABLETS
Dosage Form : TABLET
Dosage Strength : 2MG
Packaging : 60
Approval Date :
Application Number : 2458616
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : NITISINONE TABLETS
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging : 60
Approval Date :
Application Number : 2458624
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
83
PharmaCompass offers a list of Nitisinone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nitisinone manufacturer or Nitisinone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nitisinone manufacturer or Nitisinone supplier.
PharmaCompass also assists you with knowing the Nitisinone API Price utilized in the formulation of products. Nitisinone API Price is not always fixed or binding as the Nitisinone Price is obtained through a variety of data sources. The Nitisinone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nitisinone (NTBC) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nitisinone (NTBC), including repackagers and relabelers. The FDA regulates Nitisinone (NTBC) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nitisinone (NTBC) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nitisinone (NTBC) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nitisinone (NTBC) supplier is an individual or a company that provides Nitisinone (NTBC) active pharmaceutical ingredient (API) or Nitisinone (NTBC) finished formulations upon request. The Nitisinone (NTBC) suppliers may include Nitisinone (NTBC) API manufacturers, exporters, distributors and traders.
click here to find a list of Nitisinone (NTBC) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nitisinone (NTBC) DMF (Drug Master File) is a document detailing the whole manufacturing process of Nitisinone (NTBC) active pharmaceutical ingredient (API) in detail. Different forms of Nitisinone (NTBC) DMFs exist exist since differing nations have different regulations, such as Nitisinone (NTBC) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nitisinone (NTBC) DMF submitted to regulatory agencies in the US is known as a USDMF. Nitisinone (NTBC) USDMF includes data on Nitisinone (NTBC)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nitisinone (NTBC) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nitisinone (NTBC) suppliers with USDMF on PharmaCompass.
A Nitisinone (NTBC) written confirmation (Nitisinone (NTBC) WC) is an official document issued by a regulatory agency to a Nitisinone (NTBC) manufacturer, verifying that the manufacturing facility of a Nitisinone (NTBC) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nitisinone (NTBC) APIs or Nitisinone (NTBC) finished pharmaceutical products to another nation, regulatory agencies frequently require a Nitisinone (NTBC) WC (written confirmation) as part of the regulatory process.
click here to find a list of Nitisinone (NTBC) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nitisinone (NTBC) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nitisinone (NTBC) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nitisinone (NTBC) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nitisinone (NTBC) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nitisinone (NTBC) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nitisinone (NTBC) suppliers with NDC on PharmaCompass.
Nitisinone (NTBC) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nitisinone (NTBC) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nitisinone (NTBC) GMP manufacturer or Nitisinone (NTBC) GMP API supplier for your needs.
A Nitisinone (NTBC) CoA (Certificate of Analysis) is a formal document that attests to Nitisinone (NTBC)'s compliance with Nitisinone (NTBC) specifications and serves as a tool for batch-level quality control.
Nitisinone (NTBC) CoA mostly includes findings from lab analyses of a specific batch. For each Nitisinone (NTBC) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nitisinone (NTBC) may be tested according to a variety of international standards, such as European Pharmacopoeia (Nitisinone (NTBC) EP), Nitisinone (NTBC) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nitisinone (NTBC) USP).